These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

360 related articles for article (PubMed ID: 20046572)

  • 1. Combination bortezomib and rituximab treatment affects multiple survival and death pathways to promote apoptosis in mantle cell lymphoma.
    Alinari L; White VL; Earl CT; Ryan TP; Johnston JS; Dalton JT; Ferketich AK; Lai R; Lucas DM; Porcu P; Blum KA; Byrd JC; Baiocchi RA
    MAbs; 2009; 1(1):31-40. PubMed ID: 20046572
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase 2 trial of rituximab and bortezomib in patients with relapsed or refractory mantle cell and follicular lymphoma.
    Baiocchi RA; Alinari L; Lustberg ME; Lin TS; Porcu P; Li X; Johnston JS; Byrd JC; Blum KA
    Cancer; 2011 Jun; 117(11):2442-51. PubMed ID: 24048792
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proteasome inhibition with bortezomib: a new therapeutic strategy for non-Hodgkin's lymphoma.
    Leonard JP; Furman RR; Coleman M
    Int J Cancer; 2006 Sep; 119(5):971-9. PubMed ID: 16557600
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sequence-dependent synergy of the proteasome inhibitor bortezomib and cytarabine in mantle cell lymphoma.
    Weigert O; Pastore A; Rieken M; Lang N; Hiddemann W; Dreyling M
    Leukemia; 2007 Mar; 21(3):524-8. PubMed ID: 17268531
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphoma.
    Heider U; von Metzler I; Kaiser M; Rosche M; Sterz J; Rötzer S; Rademacher J; Jakob C; Fleissner C; Kuckelkorn U; Kloetzel PM; Sezer O
    Eur J Haematol; 2008 Feb; 80(2):133-42. PubMed ID: 18005386
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Constitutive and B-cell receptor-induced activation of STAT3 are important signaling pathways targeted by bortezomib in leukemic mantle cell lymphoma.
    Baran-Marszak F; Boukhiar M; Harel S; Laguillier C; Roger C; Gressin R; Martin A; Fagard R; Varin-Blank N; Ajchenbaum-Cymbalista F; Ledoux D
    Haematologica; 2010 Nov; 95(11):1865-72. PubMed ID: 20663948
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Marked clinical activity of the proteasome inhibitor bortezomib in patients with follicular and mantle-cell lymphoma.
    O'Connor OA
    Clin Lymphoma Myeloma; 2005 Nov; 6(3):191-9. PubMed ID: 16354324
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The proteasome inhibitor bortezomib targets cell cycle and apoptosis and acts synergistically in a sequence-dependent way with chemotherapeutic agents in mantle cell lymphoma.
    Hutter G; Rieken M; Pastore A; Weigert O; Zimmermann Y; Weinkauf M; Hiddemann W; Dreyling M
    Ann Hematol; 2012 Jun; 91(6):847-56. PubMed ID: 22231280
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status.
    Pérez-Galán P; Roué G; Villamor N; Montserrat E; Campo E; Colomer D
    Blood; 2006 Jan; 107(1):257-64. PubMed ID: 16166592
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Effects of the phosphoinostitide-3'-kinase delta inhibitor, CAL-101, in combination with Bortezomib on mantle lymophma cells and exploration of its related mechanism].
    Qu F; Xia B; Li X; Guo S; Zhang L; Tian C; Yu Y; Zhang Y
    Zhonghua Zhong Liu Za Zhi; 2015 Jun; 37(6):412-7. PubMed ID: 26463142
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Proteasome inhibitors].
    Alexandre J
    Rev Med Interne; 2005 Oct; 26(10):812-5. PubMed ID: 16129520
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Bruton tyrosine kinase (BTK) inhibitor PCI-32765 synergistically increases proteasome inhibitor activity in diffuse large-B cell lymphoma (DLBCL) and mantle cell lymphoma (MCL) cells sensitive or resistant to bortezomib.
    Dasmahapatra G; Patel H; Dent P; Fisher RI; Friedberg J; Grant S
    Br J Haematol; 2013 Apr; 161(1):43-56. PubMed ID: 23360303
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The novel proteasome inhibitor carfilzomib induces cell cycle arrest, apoptosis and potentiates the anti-tumour activity of chemotherapy in rituximab-resistant lymphoma.
    Gu JJ; Hernandez-Ilizaliturri FJ; Kaufman GP; Czuczman NM; Mavis C; Skitzki JJ; Czuczman MS
    Br J Haematol; 2013 Sep; 162(5):657-69. PubMed ID: 23826755
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment-induced oxidative stress and cellular antioxidant capacity determine response to bortezomib in mantle cell lymphoma.
    Weniger MA; Rizzatti EG; Pérez-Galán P; Liu D; Wang Q; Munson PJ; Raghavachari N; White T; Tweito MM; Dunleavy K; Ye Y; Wilson WH; Wiestner A
    Clin Cancer Res; 2011 Aug; 17(15):5101-12. PubMed ID: 21712452
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bortezomib is synergistic with rituximab and cyclophosphamide in inducing apoptosis of mantle cell lymphoma cells in vitro and in vivo.
    Wang M; Han XH; Zhang L; Yang J; Qian JF; Shi YK; Kwak LW; Romaguera J; Yi Q
    Leukemia; 2008 Jan; 22(1):179-85. PubMed ID: 17898787
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence of bortezomib-resistant constitutive NF-kappaB activity in mantle cell lymphoma.
    Yang DT; Young KH; Kahl BS; Markovina S; Miyamoto S
    Mol Cancer; 2008 May; 7():40. PubMed ID: 18489772
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bortezomib modulates surface CD20 in B-cell malignancies and affects rituximab-mediated complement-dependent cytotoxicity.
    Bil J; Winiarska M; Nowis D; Bojarczuk K; Dabrowska-Iwanicka A; Basak GW; Sułek K; Jakobisiak M; Golab J
    Blood; 2010 May; 115(18):3745-55. PubMed ID: 20200358
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bortezomib in mantle cell lymphoma.
    Suh KS; Goy A
    Future Oncol; 2008 Apr; 4(2):149-68. PubMed ID: 18407730
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synergistic anticancer effects of arsenic trioxide with bortezomib in mantle cell lymphoma.
    Jung HJ; Chen Z; McCarty N
    Am J Hematol; 2012 Dec; 87(12):1057-64. PubMed ID: 22965904
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Degrasyn potentiates the antitumor effects of bortezomib in mantle cell lymphoma cells in vitro and in vivo: therapeutic implications.
    Pham LV; Tamayo AT; Li C; Bornmann W; Priebe W; Ford RJ
    Mol Cancer Ther; 2010 Jul; 9(7):2026-36. PubMed ID: 20606045
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.